Gastric cancer (GC) is still one of the most prevalent cancers worldwide, with a high mortality rate, despite improvements in diagnostic and therapeutic strategies. To diminish the GC burden, a modification of the current diagnostic paradigm, and especially endoscopic diagnosis of symptomatic individuals, is necessary. In this review article, we present a broad review and the current knowledge status on serum biomarkers, including pepsinogens, gastrin, Gastropanel®, autoantibodies, and novel biomarkers, allowing us to estimate the risk of gastric precancerous conditions (GPC)—atrophic gastritis and gastric intestinal metaplasia. The aim of the article is to emphasize the role of non-invasive testing in GC prevention. This comprehensive review describes the pathophysiological background of investigated biomarkers, their status and performance based on available data, as well as their clinical applicability. We point out future perspectives of non-invasive testing and possible new biomarkers opportunities.
尽管诊断和治疗策略有所改进，胃癌仍是全球范围内最常见的癌症之一，死亡率居高不下。为减轻胃癌负担，有必要改进现有诊断模式，尤其是有症状患者的内镜诊断。本文综述了血清生物标志物的研究现状，包括胃蛋白酶原、胃泌素、胃功能检测组合、自身抗体及新型标志物，这些指标有助于评估胃癌前病变（如萎缩性胃炎和肠上皮化生）的风险。本文旨在强调无创检测在胃癌预防中的作用，系统阐述了相关生物标志物的病理生理学基础、现有数据支持下的检测效能及临床应用价值，并展望了无创检测的未来发展方向及潜在新型标志物的应用前景。
Non-Invasive Markers for the Detection of Gastric Precancerous Conditions
肿瘤(癌症)患者之家